

REFERENCES

- [1] Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983): 868-71.
- [2] Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984): 500-3.
- [3] Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220 (1983): 865-7.
- [4] UNAIDS/WHO. AIDS Epidemic Update2008: Available from: <http://www.unaids.org>.
- [5] Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339 (1998): 405-6.
- [6] Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998): 853-60.
- [7] Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. Aids 19 (2005): 487-94.
- [8] Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 (2002): 385-94.
- [9] Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Jama 282 (1999): 1142-9.
- [10] Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-

- infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. *Clin Infect Dis* 40 (2005): 468-74.
- [11] Vignoles M, Barboni G, Agosti MR, Quarleri J, Garcia MK, Giraudi V, et al. High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children. *Antivir Ther* 12 (2007): 1133-7.
- [12] Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. *Science* 267 (1995): 483-9.
- [13] Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. *Proc Natl Acad Sci U S A* 98 (2001): 176-81.
- [14] Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. *Clin Infect Dis* 48 (2009): 239-47.
- [15] Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. *N Engl J Med* 340 (1999): 1614-22.
- [16] Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. *Proc Natl Acad Sci U S A* 97 (2000): 10948-53.
- [17] Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. *PLoS Med* 5 (2008): e158.
- [18] Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. *J Infect Dis* 192 (2005): 24-9.
- [19] Korn K, Reil H, Walter H, Schmidt B. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples

- reveals problems with detecting minority species and interpretation of test results. *J Clin Microbiol* 41 (2003): 3559-65.
- [20] Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. *AIDS Res Hum Retroviruses* 18 (2002): 243-8.
- [21] Phanuphak P, Locharernkul C, Panmuong W, Wilde H. A report of three cases of AIDS in Thailand. *Asian Pac J Allergy Immunol* 3 (1985): 195-9.
- [22] Sukasem C, Churdboonchart V, Chasombat S, Kohreanudom S, Watitpun C, Pasomsub E, et al. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. *Infection* 35 (2007): 81-8.
- [23] Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. *AIDS Res Hum Retroviruses* 25 (2009): 1193-6.
- [24] Praparattanapan J, Tragoolpua Y, Pathom-aree W, Kotarathitithum W, Chaiwarith R, Nuntachit N, et al. Current molecular epidemiology and recombination of HIV type 1 subtypes in northern Thailand. *AIDS Res Hum Retroviruses* 27 (2011): 1201-6.
- [25] Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB. Adherence to antiretroviral medication among HIV-positive patients in Thailand. *J Acquir Immune Defic Syndr* 43 Suppl 1 (2006): S119-22.
- [26] Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. *Southeast Asian J Trop Med Public Health* 37 (2006): 704-15.
- [27] Sirivichayakul S, Phanuphak P, Pankam T, R OC, Sutherland D, Ruxrungtham K. HIV drug resistance transmission threshold survey in Bangkok, Thailand. *Antivir Ther* 13 Suppl 2 (2008): 109-13.

- [28] Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, Ikuta K, Sawanpanyalert P, Kameoka M. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. *AIDS Res Hum Retroviruses* 25 (2009): 625-31.
- [29] Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, et al. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. *HIV Med* 9 (2008): 322-5.
- [30] Apisarnthanarak A, Mundy LM. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. *Clin Infect Dis* 46 (2008): 1630-1.
- [31] Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. *Clin Infect Dis* 44 (2007): 447-52.
- [32] Clavel F, Hance AJ. HIV drug resistance. *N Engl J Med* 350 (2004): 1023-35.
- [33] Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. *Clin Infect Dis* 48 (2009): 931-9.
- [34] Cabrera C. Raltegravir, an HIV-1 integrase inhibitor for HIV infection. *Curr Opin Investig Drugs* 9 (2008): 885-98.
- [35] Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. *Lancet* 369 (2007): 1261-9.
- [36] Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. *N Engl J Med* 359 (2008): 339-54.
- [37] Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. *N Engl J Med* 365 (2011): 637-46.

- [38] Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. *J Virol* 83 (2009): 11440-6.
- [39] Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. *N Engl J Med* 359 (2008): 355-65.
- [40] Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. *Infect Drug Resist* 4 (2011): 65-76.
- [41] Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. *AIDS* 23 (2009): 455-60.
- [42] Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. *J Antimicrob Chemother* 63 (2009): 795-804.
- [43] Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, et al. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. *PLoS One* 5 (2010): e10311.
- [44] Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. *J Acquir Immune Defic Syndr* 55 (2010): 148-55.
- [45] Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. *Nucleic Acids Res* 37 (2009): 1193-201.
- [46] Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. *J Virol* 83 (2009): 10245-9.
- [47] Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. *J Infect Dis* 203 (2011): 1204-14.
- [48] Imaz A, del Saz SV, Ribas MA, Curran A, Caballero E, Falco V, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue

- regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 52 (2009): 382-6.
- [49] Di Biagio A, Bruzzone B, Rosso R, Vigano O, Icardi G, Viscoli C, et al. Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS 22 (2008): 355-7.
- [50] Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 11 (2009): 17-29.
- [51] Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, et al. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother 66 (2011): 1481-3.
- [52] Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55 (2011): 813-21.
- [53] Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 14 (2009): 123-9.
- [54] van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41 (2006): 352-60.
- [55] Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81 (2007): 10209-19.
- [56] Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 358 (2008): 1590-602.
- [57] Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 83 (2011): 751-9.

- [58] Vachot L, Ataman-Onal Y, Terrat C, Durand PY, Ponceau B, Biron F, et al. Short communication: retrospective study to time the introduction of HIV type 1 non-B subtypes in Lyon, France, using env genes obtained from primary infection samples. *AIDS Res Hum Retroviruses* 20 (2004): 687-91.
- [59] Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience. *Antiviral Res* 90 (2011): 164-7.
- [60] Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. *J Antimicrob Chemother* 65 (2010): 320-6.
- [61] Nouhin J, Donchai T, Hoang KT, Ken S, Kamkorn J, Tran T, et al. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. *Infect Genet Evol* 11 (2011): 38-43.
- [62] Pneumocystis Pneumonia - Los Angeles. *MMWR Weekly*. 1981 June 5:1-3
- [63] Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A. *MMWR Weekly*. 1982 July 16.
- [64] Marx JL. New disease baffles medical community. *Science* 217 (1982): 618-21.
- [65] Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. *Science* 225 (1984): 840-2.
- [66] Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, et al. Human immunodeficiency viruses. *Science* 232 (1986): 697.
- [67] Hoffmann C, Rockstroh JK, Kamps BS. HIV Medicine: Flying Publisher; 2007. Available from: www.HIVmedicine.com.
- [68] Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. *Aids* 13 Suppl A (1999): S69-84.

- [69] Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 85 (2011): 1403-7.
- [70] Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Leme V, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 15 (2009): 871-2.
- [71] Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2 (2002): 461-71.
- [72] Takebe Y, Uenishi R, Li X. Global molecular epidemiology of HIV: understanding the genesis of AIDS pandemic. Adv Pharmacol 56 (2008): 1-25.
- [73] Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 355 (2000): 2061-6.
- [74] Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. Harrison's Principles of Internal Medicine 2008. Available from: <http://www.accessmedicine.com>.
- [75] Levy JA. HIV and the Pathogenesis of AIDS. 3rd ed: ASM Press, American Society for Microbiology; 2007.
- [76] Turner BG, Summers MF. Structural biology of HIV. J Mol Biol 285 (1999): 1-32.
- [77] Wieggers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 72 (1998): 2846-54.
- [78] Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 68 (1994): 8017-27.
- [79] Flexner C. HIV-protease inhibitors. N Engl J Med 338 (1998): 1281-92.
- [80] Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73 (2008): 789-800.

- [81] Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 7 (2005): 139-47.
- [82] Weiss CD. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev 5 (2003): 214-21.
- [83] Qadir MI, Malik SA. HIV fusion inhibitors. Rev Med Virol 20 (2010): 23-33.
- [84] Metifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses 2 (2010): 1347-66.
- [85] Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 99 (2002): 6661-6.
- [86] Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77 (2003): 5037-8.
- [87] Siliciano RF. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top HIV Med 13 (2005): 96-100.
- [88] Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171 (1995): 1411-9.
- [89] Schinazi RF, Lloyd RM, Jr., Nguyen MH, Cannon DL, McMillan A, Ilksoy N, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 37 (1993): 875-81.
- [90] Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. Aids 14 (2000): 163-71.
- [91] Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine

- monotherapy for 1 to 2 years. Antimicrob Agents Chemother 41 (1997): 757-62.
- [92] Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). Jama 283 (2000): 205-11.
- [93] Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Jama 283 (2000): 229-34.
- [94] Gulick RM, Ribaldo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350 (2004): 1850-61.
- [95] Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74 (2000): 6262-8.
- [96] Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 6 (2001): 115-26.
- [97] Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 74 (2000): 3579-85.
- [98] Diallo K, Gotte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 47 (2003): 3377-83.
- [99] Miller V, Stark T, Loeliger AE, Lange JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 3 (2002): 135-45.
- [100] Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 6 (1999): R137-46.

- [101] Larder BA, Stammers DK. Closing in on HIV drug resistance. Nat Struct Biol 6 (1999): 103-6.
- [102] Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 188 (2003): 992-1000.
- [103] Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 45 (2001): 1836-42.
- [104] Tamalet C, Yahy N, Tourres C, Colson P, Quinson AM, Poizot-Martin I, et al. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 270 (2000): 310-6.
- [105] Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 20 (2001): 1025-8.
- [106] Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70 (1996): 1086-90.
- [107] Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 6 Suppl 3 (2001): 25-44.
- [108] Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 (1995): 696-9.
- [109] Bachelier LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44 (2000): 2475-84.

- [110] Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. *J Virol* 67 (1993): 2412-20.
- [111] Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. *Aids* 14 (2000): F111-5.
- [112] Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. *J Infect Dis* 186 (2002): 181-8.
- [113] Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. *Antimicrob Agents Chemother* 54 (2010): 718-27.
- [114] Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 48 (2004): 4680-6.
- [115] Fulco PP, McNicholl IR. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. *Pharmacotherapy* 29 (2009): 281-94.
- [116] Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. *Aids* 24 (2010): 503-14.
- [117] Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Bethune MP, et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the

- DUET-1 and DUET-2 clinical studies. *AIDS Res Hum Retroviruses* 26 (2010): 1197-205.
- [118] Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. *Antimicrob Agents Chemother* 55 (2011): 600-7.
- [119] Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. *J Acquir Immune Defic Syndr* 58 (2011): 18-22.
- [120] Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. *Proc Natl Acad Sci U S A* 91 (1994): 5597-601.
- [121] Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. *Antimicrob Agents Chemother* 39 (1995): 1704-10.
- [122] Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. *J Virol* 72 (1998): 5154-64.
- [123] Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. *J Virol* 80 (2006): 4909-20.
- [124] Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother* 46 (2002): 1896-905.

- [125] Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. *Aids* 18 (2004): 1787-94.
- [126] Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. *J Clin Virol* 34 (2005): 295-301.
- [127] Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. *J Antimicrob Chemother* 57 (2006): 619-27.
- [128] Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. *Antimicrob Agents Chemother* 53 (2009): 4522-4.
- [129] Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. *Antimicrob Agents Chemother* 54 (2010): 491-501.
- [130] Delaugerre C. Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor. *Med Mal Infect* 40 Suppl 1 (2010): S1-10.
- [131] Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. *Aids* 17 (2003): F1-5.
- [132] Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. *Curr Med Chem* 12 (2005): 1705-19.
- [133] Walter H, Low P, Harrer T, Schmitt M, Schwingel E, Tschochner M, et al. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. *J Acquir Immune Defic Syndr* 31 (2002): 137-46.
- [134] Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. *J Virol* 75 (2001): 6410-7.

- [135] Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 100 (2003): 8401-6.
- [136] Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 99 (2002): 7015-20.
- [137] Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A 98 (2001): 658-63.
- [138] Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (1997): 1291-5.
- [139] Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 (1999): 512-7.
- [140] Albrecht D, Zollner B, Feucht HH, Lorenzen T, Laufs R, Stoehr A, et al. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol 24 (2002): 93-8.
- [141] Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. Jama 282 (1999): 1135-41.
- [142] Veenstra J, Schuurman R, Cornelissen M, van't Wout AB, Boucher CA, Schuitemaker H, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 21 (1995): 556-60.

- [143] Pao D, Andraday U, Clarke J, Dean G, Drake S, Fisher M, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 37 (2004): 1570-3.
- [144] Delaugerre C, Marcelin AG, Soulie C, Chaix ML, Katlama C, Girard PM, et al. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey. Aids 21 (2007): 1365-7.
- [145] Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. Aids 18 (2004): 447-57.
- [146] Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. Aids 19 (2005): 1819-25.
- [147] Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192 (2005): 16-23.
- [148] Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 (2007): 135-47.
- [149] Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38 (2005): 37-42.
- [150] Li JZ, Paredes R, Ribaud HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. Jama 305 (2011): 1327-35.
- [151] Peuchant O, Thiebaut R, Capdepon S, Lavignolle-Aurillac V, Neau D, Morlat P, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. Aids 22 (2008): 1417-23.

- [152] Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, et al. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 24 (2010): 867-73.
- [153] Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 54 (2010): 3938-48.
- [154] Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, et al. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. Aids 24 (2010): 2651-6.
- [155] Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 146 (2007): 136-46.
- [156] Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43 (2005): 406-13.
- [157] Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, Delwart EL. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol 78 (2004): 7112-23.
- [158] Garcia-Bujalance S, de Guevara CL, Gonzalez-Garcia J, Arribas JR, Gutierrez A. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. J Clin Microbiol 43 (2005): 4186-8.
- [159] Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41 (1997): 284-91.

- [160] Halfon P, Durant J, Clevenbergh P, Carsenti H, Celis L, Khiri H, et al. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. *Aids* 17 (2003): 1351-61.
- [161] Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. *J Clin Microbiol* 36 (1998): 569-72.
- [162] Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, et al. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. *J Clin Microbiol* 40 (2002): 1413-9.
- [163] Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. *PLoS One* 2 (2007): e638.
- [164] Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. *J Infect Dis* 199 (2009): 693-701.
- [165] Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. *Genome Res* 17 (2007): 1195-201.
- [166] Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. *PLoS One* 4 (2009): e6079.
- [167] Garcia-Gonzalez C, Garcia-Bujalance S, Ruiz-Carrascoso G, Arribas JR, Gonzalez-Garcia J, Bernardino JI, et al. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. *Diagn Microbiol Infect Dis* (2011).
- [168] White HE, Durston VJ, Seller A, Fratter C, Harvey JF, Cross NC. Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. *Genet Test* 9 (2005): 190-9.

- [169] Gruber JD, Colligan PB, Wolford JK. Estimation of single nucleotide polymorphism allele frequency in DNA pools by using Pyrosequencing. Hum Genet 110 (2002): 395-401.
- [170] Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, Levenson C, et al. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18 (1990): 999-1005.
- [171] Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42 (2004): 4788-95.
- [172] Lavebratt C, Sengul S, Jansson M, Schalling M. Pyrosequencing-based SNP allele frequency estimation in DNA pools. Hum Mutat 23 (2004): 92-7.
- [173] Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW, Hegerich PA, et al. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol 70 (1996): 5935-43.
- [174] Lavebratt C, Sengul S. Single nucleotide polymorphism (SNP) allele frequency estimation in DNA pools using Pyrosequencing. Nat Protoc 1 (2006): 2573-82.
- [175] Lackenby A, Democratis J, Siqueira MM, Zambon MC. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 13 (2008): 809-20.
- [176] Drummond AJ, Ashton B, Buxton S, Cheung M, Cooper A, Duran C, et al. Geneious v5.4. Available from <http://www.geneious.com>.
- [177] Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18 (2010): 156-63.
- [178] Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52 (2008): 1351-8.
- [179] Heneine W. When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis 201 (2010): 647-9.

- [180] Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. *J Virol* 78 (2004): 4234-47.
- [181] Gianella S, Richman DD. Minority variants of drug-resistant HIV. *J Infect Dis* 202 (2010): 657-66.
- [182] Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, et al. Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. *Jpn J Infect Dis* 60 (2007): 284-9.
- [183] Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. *J Antimicrob Chemother* 65 (2010): 2620-7.
- [184] Toni TA, Asahchop EL, Moisi D, Ntemgwa M, Oliveira M, Masquelier B, et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. *Antimicrob Agents Chemother* 53 (2009): 1670-2.
- [185] Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, et al. Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. *PLoS One* 5 (2010): e15510.
- [186] Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. *J Infect Dis* 201 (2010): 1063-71.
- [187] Paredes R, Lalama CM, Ribaldo HJ, Schackman BR, Shikuma C, Giguel F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. *J Infect Dis* 201 (2010): 662-71.
- [188] Waters L, Nelson M. Why do patients fail HIV therapy? *Int J Clin Pract* 61 (2007): 983-90.

- [189] del Rio C. Current concepts in antiretroviral therapy failure. Top HIV Med 14 (2006): 102-6.
- [190] King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naïve, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 191 (2005): 2046-52.
- [191] Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5 (2010): e11345.
- [192] Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol 50 (2011): 156-61.
- [193] Bunupuradah T, Chetchotisakd P, Munsakul W, Jirajariyavet S, KP, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Ruxrungtham K. Second-line LPV/r monotherapy was inferior to TDF/3TC/LPV/r in patients who failed NNRTI regimen: HIV STAR study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2011).
- [194] Mukherjee R, Jensen ST, Male F, Bittinger K, Hodinka RL, Miller MD, et al. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 25 (2011): 1951-9.
- [195] Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46 (2007): 125-33.
- [196] Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, et al. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 23 (2009): 2159-64.
- [197] Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz J Infect Dis 14 (2010): 513-8.

- [198] Piralla A, Paolucci S, Gulminetti R, Comolli G, Baldanti F. HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virology 8 (2011): 149.
- [199] Sato A, Kobayashi M, Yoshinaga T, Fujiwara T, Underwood M, Johns, B., Foster, S., Hazen, R., Ferris, R., Brown, K., Garvey, E. S/GSK1349572 is a potent next generation HIV integrase inhibitor. Program and Abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa 2009.
- [200] Sato A, Kobayashi M, Seki T, Morimoto CW, Yoshinaga T, Fujiwara, T., Johns, B.A., Underwood, M. S/GSK1349572: A next generation integrase inhibitor (INI) with limited or no-cross resistance to first generation INIs or other classes of antivirals Program and Abstracts of the 8th European HIV Drug Resistance Workshop; Sorrento, Italy 2010.
- [201] Marcelin AG MI, Fabeni L, et al. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitor-naïve and raltegravir-experienced patients. 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco 2010.
- [202] da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65 (2010): 1262-9.

BIOGRAPHY

First name: Hai
 Middle name: Le
 Last name: Nguyen
 Birth date: November 4, 1973
 Nationality: Vietnam
 E-mail address: nguyenlehai@yahoo.com, HaiN@nihe.org.vn

EDUCATION

School/University	Location	Dates of Attendance	Degree/Certification Received
Hanoi Medical University (full scholarship)	Hanoi, Vietnam	1990-1996	Medical Doctor
University of Illinois at Chicago (full scholarship)	Chicago, US	2002-2004	M.P.H (Major: Epidemiology)
Chulalongkorn University, Faculty of Medicine and University Paris Diderot (Paris 7), Saint Louis Hospital (full scholarship)	Bangkok, Thailand; Paris, France	6/2008-present	Ph.D student

RESEARCH GRANTS

The commission of Higher ducation (CHE), Thailand.
 The Royal Golden Jubilee Ph.D Program, the Thailand Research Fund.
 The Thailand International Development Cooperation Agency (TICA)
 French Embassy in Bangkok, Thailand
 Université Paris Diderot -Institut des études doctorales

PUBLICATIONS

Hai Le Nguyen, Patrawadee Pitakpolrat, Sunee Sirivichayakul, Constance Delaugerre, Kiat Ruxrungham. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line ARV therapy with no detectable resistance-associated mutations in Thailand. *J Med Virol*. 2012 May;84(5):713-20.

Hai Le Nguyen, Kiat Ruxrungham, Constance Delaugerre. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. *Intervirology*. 2012 Mar 23. [Epub ahead of print]

